Telomir Pharmaceuticals, Inc. Common StockTELONASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank75
3Y CAGR+131.1%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+131.1%/yr
Annual compound
Percentile
P75
Within normal range
vs 3Y Ago
12.3x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$10.54M-13.9%
2024$12.24M+210.6%
2023$3.94M+361.5%
2022$854147.00+518.4%
2021$138131.00-